Athira Pharma Inc
NASDAQ:ATHA
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.6275
  • TODAY'S CHANGE (%)
    -0.0145 (-2.2586%)
  • Bid / Lots
    0.6156/ 5
  • Ask / Lots
    0.6500/ 50
  • Open / Previous Close
    0.6300 / 0.6420
  • Day Range
    0.6156
    0.6500
  • 52 Week Range
    0.4115
    4.2984
  • Volume
    333,985

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: ATHA

      206-769-9219
      Athira Pharma, Inc. Condensed Consolidated Balance Sheets (Amounts in thousands) September 30, December 31, 2024 2023 --------------- -------------- (unaudited) Assets Cash and cash equivalents $ 68,856 $ 90,584 Short-term investments -- 56,835 Other short-term assets 13,146 7,310 Other long-term assets 4,244 5,516 ----------- ---------- Total assets $ 86,264 $ 160,245 =========== ========== Liabilities and stockholders' equity Current liabilities $ 27,751 $ 28,840 Long-term liabilities 912 1,217 ----------- ---------- Total liabilities 28,663 30,057 Stockholders' equity 57,583 130,188 ----------- ---------- Total liabilities and stockholders' equity $ 86,246 $ 160,245 =========== ========== Athira Pharma, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Amounts in thousands, except share and per share amounts) (Unaudited) Three Months Ended September 30, ---------------------------- 2024 2023 ------------ -------------- Operating expenses: Research and development $ 17,922 $ 27,202 General and administrative 7,572 7,840 Legal expense 4,127 -- Total operating expenses 29,621 35,042 ---------- ---------- Loss from operations (29,621) (35,042) Other income, net 880 2,072 Net loss $ (28,741) $ (32,970) ========== ========== Unrealized gain on available-for-sale securities 41 261 ---------- ---------- Comprehensive loss attributable to common stockholders $ (28,700) $ (32,709) ========== ========== Net loss per share attributable to common stockholders, basic and diluted $ (0.75) $ (0.87) ========== ========== Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 38,517,602 38,054,583 ========== ==========

    • 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: ATHA

      206-769-9219
      Athira Pharma, Inc. Condensed Consolidated Balance Sheets (Amounts in thousands) September 30, December 31, 2024 2023 --------------- -------------- (unaudited) Assets Cash and cash equivalents $ 68,856 $ 90,584 Short-term investments -- 56,835 Other short-term assets 13,146 7,310 Other long-term assets 4,244 5,516 ----------- ---------- Total assets $ 86,264 $ 160,245 =========== ========== Liabilities and stockholders' equity Current liabilities $ 27,751 $ 28,840 Long-term liabilities 912 1,217 ----------- ---------- Total liabilities 28,663 30,057 Stockholders' equity 57,583 130,188 ----------- ---------- Total liabilities and stockholders' equity $ 86,246 $ 160,245 =========== ========== Athira Pharma, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Amounts in thousands, except share and per share amounts) (Unaudited) Three Months Ended September 30, ---------------------------- 2024 2023 ------------ -------------- Operating expenses: Research and development $ 17,922 $ 27,202 General and administrative 7,572 7,840 Legal expense 4,127 -- Total operating expenses 29,621 35,042 ---------- ---------- Loss from operations (29,621) (35,042) Other income, net 880 2,072 Net loss $ (28,741) $ (32,970) ========== ========== Unrealized gain on available-for-sale securities 41 261 ---------- ---------- Comprehensive loss attributable to common stockholders $ (28,700) $ (32,709) ========== ========== Net loss per share attributable to common stockholders, basic and diluted $ (0.75) $ (0.87) ========== ========== Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted 38,517,602 38,054,583 ========== ==========

Peers Headlines